NCT04629339: A reported trial by Incyte Corporation
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04629339 |
|---|---|
| Title | A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 2, 2021 |
| Completion date | March 26, 2024 |
| Required reporting date | March 26, 2025, midnight |
| Actual reporting date | Feb. 24, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |